M&A Deal Summary

Liminal BioSciences Acquires Telesta Therapeutics

On August 24, 2016, Liminal BioSciences acquired life science company Telesta Therapeutics

Acquisition Highlights
  • This is Liminal BioSciences’ 2nd transaction in the Life Science sector.
  • This is Liminal BioSciences’ 2nd transaction in Canada.
  • This is Liminal BioSciences’ 1st transaction in Quebec.

M&A Deal Summary
Date 2016-08-24
Target Telesta Therapeutics
Sector Life Science
Buyer(s) Liminal BioSciences
Deal Type Add-on Acquisition

Target

Telesta Therapeutics

Saint-Laurent, Quebec, Canada
Telesta Therapeutics, Inc. is a clinical stage biotechnology company focused on the development, manufacturing, and commercialization of proprietary and innovative therapeutics for the global human health market. The Company’s anchor product is in Phase III clinical development to treat non-muscle-invasive bladder cancer.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Liminal BioSciences

Laval, Quebec, Canada
Category Company
Founded 1994
Sector Life Science
Employees251
Revenue 1M CAD (2021)
DESCRIPTION

Liminal BioSciences is a biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics, and small-molecule drug development. The Company offers its state-of-the-art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics. Liminal BioSciences was founded in 1994 and is based in Laval, Canada.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 1
State (Quebec) 1 of 1
Country (Canada) 2 of 2
Year (2016) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-28 Emergent BioSolutions - Plasma Collection Facility

Winnipeg, Manitoba, Canada

Emergent’s plasma collection center is an FDA and Health Canada licensed plasma collection facility. The plasma collection center is conveniently located in close proximity to the existing Emergent Winnipeg based cGMP manufacturing facility, which was recently announced as providing ProMetic with up to 250,000 liters of annual plasma processing capacity.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-10-15 Prometic Bioproduction

Laval, Quebec, Canada

Prometic Bioproduction has developed the first-ever FDA-approved treatment for Congenital Plasminogen Deficiency. The new drug, called Ryplazim has been approved for the treatment of all the clinical manifestations of Plasminogen Deficiency, which can lead to blindness, respiratory failure, and other severe complications.

Sell -
Mergr

Product

Company

Legal